Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Edetate Calcium Disodium Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

NCT07191262
View directory record Official record
Conditions
Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth
Interventions
0.12% CHX and Essential Oil mouthrinse, 2.6% EDTA and 0.2% EDTA mouth rinse
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

NCT02248051
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Anaheim, California • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)

NCT01902953
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Lymphoseek and VBD Sln dissection
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 8, 2026, 10:05 PM EDT
Recruiting Phase 1 Interventional

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

NCT03630991
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome
Interventions
Edetate Calcium Disodium, Multivitamin, Succimer
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

NCT01106040
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 8, 2026, 10:05 PM EDT
Withdrawn Not applicable Interventional

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

NCT01416740
View directory record Official record
Conditions
Shoulder Pain
Interventions
Indirect MRA of shoulder, Gadopentetate Dimeglumine
Procedure · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Early Phase 1 Interventional

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

NCT03424746
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease
Interventions
disodium EDTA
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Not applicable Interventional

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

NCT00004936
View directory record Official record
Conditions
Cervical Cancer
Interventions
iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
Drug · Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Sep 8, 2026, 10:05 PM EDT
Not listed Early Phase 1 Interventional

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

NCT03991520
View directory record Official record
Conditions
Endometriosis, Anakinra, Markers of Inflammation
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Terminated Phase 1 Interventional

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

NCT00477503
View directory record Official record
Conditions
Central Nervous System Tumors, Brain Tumors
Interventions
Gallium-67 Citrate (Ga-67), In-111 DTPA (In-111 pentetate)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 8, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

NCT05275686
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy 2

NCT02733185
View directory record Official record
Conditions
Diabetes, Myocardial Infarction
Interventions
disodium EDTA, Oral Multi Vitamins/Minerals (OMVM), Placebo disodium EDTA, Placebo Oral Multi Vitamins/Minerals (OMVM)
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 8, 2026, 10:05 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prolonged Gadolinium Retention After MRI Imaging

NCT02421029
View directory record Official record
Conditions
Heavy Metal Toxicity
Interventions
edetate calcium disodium
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 8, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

Repurposing Tilmanocept for Cardiac Sarcoidosis

NCT07159074
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Absorptive Clearance in the Cystic Fibrosis Airway

NCT00541190
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

NCT01982123
View directory record Official record
Conditions
Lung Carcinoma, Malignant Neoplasm
Interventions
SPECT/CT, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m DTPA
Diagnostic Test · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

NCT02798523
View directory record Official record
Conditions
Normal Physiology
Interventions
Methylprednisolone sodium succinate(Solu-Medrol), Topical methylprednisolone (Advantan emulsion 0 /1%)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

NCT00001575
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma, Non-Hodgkin
Interventions
Y-90 Humanized Anti-Tac, Calcium-DTPA
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 8, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

NCT03405142
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer
Interventions
Panitumumab-IRDye800, Lymphoseek
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 8, 2026, 10:05 PM EDT